Evaluation of the effect of Allopurinol on the frequency of ventricular and supraventricular arrhythmias

Phase 3

• Conditions: Condition 1: Ventricular arrhythmias. Condition 2: Supraventricular arrhythmia.; Re-entry ventricular arrhythmia; Supraventricular tachycardia; I47.0; I47.1

• Registration Number: IRCT20120520009801N12
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 134

Inclusion Criteria

Age more than 18 years and less than 70 years
Having an implantable cardioverter-defibrillator for more than 3 months before starting participation in the clinical trial
Obtain informed consent from the patient

Exclusion Criteria

Taking the drug allopurinol before
Moderate to severe kidney dysfunction (GFR < 60 ml/min/1.73m2)
Significant impairment of liver function (Child-Pugh class B or C)
Previous history of severe skin reactions like Steven Johnson
Pregnancy or suspected pregnancy
Active inflammation or infection
Suffering from autoimmune diseases and malignancies
Taking class I and III antiarrhythmic drugs
Performing major surgeries
Taking any medication with anti-inflammatory effect

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of ventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.;Frequency of supraventricular arrhythmias. Timepoint: The beginning of the study and 3 months later. Method of measurement: Examining the data obtained from the implantable cardiac defibrillator device.

Secondary Outcome Measures

Name	Time	Method
ric acid level. Timepoint: Before the intervention and after 3 months. Method of measurement: Biochemistry test of the patient's blood sample.;Blood pressure. Timepoint: Before the intervention and after 3 months. Method of measurement: sphygmomanometer.;Hospitalization. Timepoint: Before the intervention and after 3 months. Method of measurement: Pulse oximeter device.